Close Menu

NEW YORK (GenomeWeb) – The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor's susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with defective DNA repair. But not all patients respond as expected.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
10
Sponsored by
Roche

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.